Work

A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8017

Authors: Helena Alexandra Yu, Camelia S. Sima, Dalicia Reales, Shomari Jordan, Charles M. Rudin, Mark G. Kris, Franziska Michor, William Pao, Gregory J. Riely

Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2607221480

Cites:

Cited by: 11

Related to: 10